# South Korea Car T Cell Therapy Market > South Korea CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), and By End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 14.65% - **2024:** $ 250 Million - **2025:** $ 286.62 Million - **2035:** $ 1,125 Million - **Key Players:** Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Celgene (US), Amgen (US), Merck & Co. (US), AstraZeneca (GB), Janssen Pharmaceuticals (US), Bluebird Bio (US) **Report ID:** MRFR/Pharma/48108-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-car-t-cell-therapy-market-49864 --- ## Market Summary ## **South Korea****CAR T****Cell Therapy Market Overview** As per MRFR analysis, the South Korea CAR T Cell Therapy Market Size was estimated at 200 (USD Million) in 2023.The South Korea CAR T Cell Therapy Market Industry is expected to grow from 231(USD Million) in 2024 to 1,375 (USD Million) by 2035. The South Korea CAR T Cell Therapy Market CAGR (growth rate) is expected to be around 17.605% during the forecast period (2025 - 2035). ### **Key South Korea****CAR T****Cell Therapy Market Trends Highlighted** The market for CAR T cell therapy is expanding significantly in South Korea thanks to higher investments in biotechnology-related research and development. To improve its healthcare system, the South Korean government has aggressively encouraged the development of cellular therapies, especially in oncology. Initiatives to expedite regulatory procedures for novel therapies demonstrate this support, which makes it simpler for businesses to launch their goods. Funding for education and training in this specialist field as well as the dedication to growing healthcare infrastructure are important market factors that help local businesses stay up to date with developments throughout the world. Personalized medicine, which focuses on adjusting treatments to each patient's unique genetic profile, has been increasingly popular in recent years. This tendency has promoted innovation in CAR T cell products by creating new opportunities for collaboration between industry and academia. The region's growing prevalence of chronic illnesses like cancer has also raised the demand for efficient therapies, which is driving further research. Furthermore, South Korea's distinct position as a pioneer in technology and digital health integration makes it easier to produce cutting-edge solutions, which presents a chance to investigate for bettering treatment results. Given the intricate production procedures required, emphasis is being placed on investments in manufacturing capabilities for CAR T cell therapy. In order to improve accessibility, businesses are seeking to implement scalable and effective production procedures. A paradigm shift in healthcare practices is evident in South Korea's increasing knowledge and acceptance of immunotherapy as a mainstream cancer treatment, which is conducive to the expansion of CAR T Cell treatments. All things considered, these patterns highlight South Korea's aggressive strategy to establish itself as a major force in the worldwide CAR T cell therapy market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea****CAR T****Cell Therapy Market Drivers** Increasing Incidence of Cancer The South Korea CAR T Cell Therapy Market Industry is being significantly driven by the rising incidence of cancer among the population. According to the Korean Central Cancer Registry, there were approximately 234,000 new cancer cases reported in 2020 alone. This alarming figure indicates a growing need for advanced therapeutic solutions, particularly CAR T cell therapy, which has shown promising results in treating hematological malignancies. Entities such as the Korean Cancer Association are actively involved in raising awareness and supporting research, which aligns with the heightened focus on innovative treatments. The government's initiatives to enhance cancer care and investments in Research and Development for targeted therapies are further aiding this market's expansion. Given the increasing cancer prevalence, forecasts suggest that the demand for CAR T cell therapies will escalate, contributing to substantial market growth in South Korea. Advancements in Genomic Research Technological advancements in genomic research are another critical driver fueling the South Korea CAR T Cell Therapy Market Industry. With significant investments into biotechnology and genotyping technologies by major institutions such as the Korea Institute of Science and Technology, improvements in personalized medicine are on the rise. Notably, there has been a rapid increase in the number of patents filed related to CAR T cell therapies, indicating a flourishing innovation landscape. This environment fosters R&D that not only enhances the efficacy of these therapies but also expands their application in various types of cancers. As the scientific community emphasizes the importance of tailormade cancer therapies, the resulting breakthroughs in this domain are likely to boost market dynamics. Government Support for Cancer Research The South Korean government continues to play a pivotal role in shaping the future of the CAR T Cell Therapy Landscape. Through supportive regulations and funding for innovative cancer treatments, policies have been established to reinforce the infrastructure required for Research and Development. For instance, the Biohealth Industry Promotion Act, which was enacted in 2020, aims to foster an ecosystem for biotechnology development. As of 2022, over USD 400 million was allocated to support research initiatives focusing on advanced therapies, including CAR T cell advancements. This governmental backing not only accelerates development cycles but also ensures that South Korea remains competitive in the global CAR T cell landscape, appealing to both researchers and investors alike. Rise of Biotech Startups The rise of biotechnology startups specializing in CAR T cell therapies is significantly impacting the South Korea CAR T Cell Therapy Market Industry. Data from the Ministry of Health and Welfare shows that there has been a 25% increase in the number of biotech startups focusing on cancer treatment technologies over the past three years. Startups like Y-Biologics and GC Cell are gaining traction, actively bringing innovative CAR T products to market. These startups often collaborate with established pharmaceutical companies as well as research institutions to optimize their research outcomes. This influx of fresh ideas and approaches is vital for expanding the range of treatment options available in South Korea, accommodating the rising demand for state-of-the-art oncology solutions. ## **South Korea****CAR T****Cell Therapy Market Segment Insights** ### **CAR T****Cell Therapy Market Therapeutic Area Insights** The South Korea CAR T Cell Therapy Market within the Therapeutic Area segment is experiencing significant growth and transformation, driven primarily by advancements in technology and increasing clinical applications. Oncology remains at the forefront of this market, with CAR T cell therapies demonstrating notable efficacy in treating various hematologic malignancies such as leukemia and lymphoma. The success of these therapies in oncology is largely attributed to rigorous clinical trials and the establishment of specialized treatment centers across South Korea, which enhance patient access and facilitate innovative treatment protocols. In addition, Autoimmune Diseases represent an emerging area of interest within the South Korea CAR T Cell Therapy Market as researchers explore the potential for CAR T cell therapies to modify immune responses and alleviate symptoms of conditions like rheumatoid arthritis and lupus. This evolving interest reflects a broader trend within the pharmaceutical industry, emphasizing personalized medicine approaches that leverage genetic and cellular modalities for targeted interventions. Furthermore, the segment addressing Infectious Diseases is gaining traction as researchers investigate CAR T cell applications in combating viral infections and enhancing immune responses against pathogens. This area presents substantial opportunities for development, especially in the context of South Korea’s robust healthcare infrastructure and supportive government policies promoting innovative therapeutic research. Overall, the dynamic therapeutic landscape for CAR T cell therapy in South Korea demonstrates a well-rounded potential to address diverse medical needs while capitalizing on the continuous technological evolution and heightened research efforts in the region. The confluence of these factors contributes to a strong foundation for the South Korea CAR T Cell Therapy Market, positioning it well for future expansion across these therapeutic applications. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **CAR T****Cell Therapy Market Cell Source Insights** The South Korea CAR T Cell Therapy Market is witnessing significant developments in the Cell Source segment, reflecting various innovative strategies in healthcare. Autologous therapies, which involve using a patient's own cells, hold a promising position due to their personalized nature, thereby reducing the risk of rejection. Allogeneic sources derived from healthy donors are gaining traction as they have the potential for scalability and reduced treatment timelines, positioning them favorably in clinical settings. Gene-edited approaches are highlighting advancements in technology, focusing on improving the safety and efficacy of therapies, thus catering to a critical demand in the market. South Korea's robust Research and Development initiatives, supported by government investments in biotechnology, are paving the way for rapid advancements in these cell-sourcing methods. These evolving dynamics within the Cell Source segment underline its importance in enhancing patient outcomes and driving the overall growth of the South Korea CAR T Cell Therapy Market. The market trends reflect a strong inclination towards personalized medicine and genetically tailored therapies, which are becoming vital components in the approach to treating various cancers and autoimmune diseases. ### **CAR T****Cell Therapy Market Indication Insights** The South Korea CAR T Cell Therapy Market is witnessing a notable evolution in its Indication segment, which encompasses various diseases such as Acute Lymphoblastic Leukemia, non-Hodgkin lymphoma, and Multiple Myeloma. Acute Lymphoblastic Leukemia holds significant importance due to its prevalence in pediatric cases, driving a considerable demand for advanced therapeutic options. Non-Hodgkin Lymphoma, with various subtypes, is another area where CAR T Cell therapies are making remarkable advancements, providing hope for patients who have limited treatment options available. Meanwhile, Multiple Myeloma represents a critical focus area for ongoing Research and Development initiatives as the need for effective and targeted therapies continues to rise. The growth trends indicate that these therapies not only improve survival rates but also enhance the quality of life for patients. With government support and innovation from local biotechnology firms, the South Korea CAR T Cell Therapy Market is positioned to capitalize on these key indications, driven by continuous research efforts and increasing approval of therapeutic options. ### **CAR T****Cell Therapy Market****End-user****Insights** The South Korea CAR T Cell Therapy Market showcases a diverse landscape with significant engagement from various End-users such as Hospitals, Research Institutes, and Cancer Treatment Centers. Hospitals are crucial in providing immediate patient care and administering therapies, often serving as the front line for CAR T cell treatments due to their patient volume and advanced facilities. Research Institutes play an important role in advancing the scientific understanding of CAR T cell therapies, focusing on clinical trials and innovative research that aids in refining treatment protocols and improving outcomes. Cancer Treatment Centers are dedicated facilities that specialize in comprehensive cancer care, including CAR T cell therapies and are instrumental in focusing on patient-specific treatment plans, thus driving improved patient experiences and outcomes. Moreover, the continuous investment in healthcare infrastructure in South Korea, along with strong government support for medical innovation, is likely to foster growth in these areas, aiding in the effective treatment of various cancers and enhancing the overall South Korea CAR T Cell Therapy Market industry. Each segment serves a pivotal function that not only contributes to revenue generation but also addresses the diverse needs of patients requiring advanced cancer therapies, ensuring tailored approaches for treatment and care. ## **South Korea****CAR T****Cell Therapy Market Key Players and Competitive Insights** The South Korea CAR T Cell Therapy Market is experiencing significant growth due to increasing investments in advanced cancer treatment methodologies and the rising prevalence of hematological malignancies. This market showcases a competitive landscape characterized by a blend of local and international players striving to leverage innovations in cellular therapies, which have shown transformative potential in treating various forms of cancer. Companies involved in this market are focusing on research and development to enhance therapeutic efficacy while also addressing regulatory and manufacturing challenges unique to the region. The evolving landscape is propelled by collaborations, partnerships, and advancements in biomanufacturing technologies, which bolster the market's resilience against both domestic and global challenges. Allogene Therapeutics has established a notable presence in the South Korea CAR T Cell Therapy Market by leveraging its innovative allogeneic CAR T cell platform technology. The company emphasizes the development of off-the-shelf CAR T cell therapies that promise to improve accessibility for patients in need. This model not only allows for quicker treatment response but also enhances scalability and production efficiency. Allogene Therapeutics benefits from robust research capabilities and strategic partnerships within South Korea, which enhance its operational strength in a competitive market. The firm's ability to bring advanced therapeutic solutions to patients facing various malignancies showcases its commitment to improving cancer care within this growing market. Sorrento Therapeutics has made impactful strides in the South Korea CAR T Cell Therapy Market through a robust portfolio of innovative therapeutic solutions focused on cancer treatment. The company develops multiple CAR T cell therapies that prioritize both efficacy and safety, targeting various hematologic cancers while also exploring options for solid tumors. In the South Korean context, Sorrento Therapeutics is recognized for its agile approach to research and its ability to quickly adapt to market demands, along with its strategic mergers and acquisitions that bolster its presence in the region. The company’s investments in local partnerships for clinical trials and product development further solidify its foothold in the Korean market. Their emphasis on innovation, alongside a solid market presence, positions Sorrento Therapeutics as a pivotal player in advancing CAR T cell therapy options in South Korea. **Key Companies in the South Korea****CAR T****Cell Therapy Market Include** ## **South Korea****CAR T****Cell Therapy Market Industry Developments** The South Korea CAR T Cell Therapy Market has seen significant developments recently, with major companies like Bristol-Myers Squibb, Novartis, and Gilead Sciences expanding their presence. In March 2023, Allogene Therapeutics announced a collaboration with Samsung Biologics to enhance its cell therapy manufacturing capabilities in South Korea. Additionally, in April 2023, Sorrento Therapeutics initiated its CAR T Cell development program, focusing on innovative therapies in the region. Mergers and acquisitions have also been noteworthy, with KITE Pharma being acquired by Gilead Sciences in a deal that continues to influence competitive dynamics in the market. Over recent years, specifically in 2021, LG Chem strengthened its Research and Development capabilities by teaming up with local universities to foster innovation in cell therapy technologies. The South Korean government is actively supporting this sector through its Healthcare Innovation Strategy, aimed at boosting biopharmaceutical technologies and expanding access to advanced cancer treatments. The growth in this sector is also reflected in increasing investments aimed at enhancing the local manufacturing landscape for CAR T Cell therapies, thereby improving patient access and treatment options. ## **South Korea****CAR T****Cell Therapy Market Segmentation Insights** ### **CAR T****Cell Therapy Market Therapeutic Area****Outlook** ### **CAR T****Cell Therapy Market Cell Source****Outlook** ### **CAR T****Cell Therapy Market Indication****Outlook** ### **CAR T****Cell Therapy Market****End-user****Outlook** ## Market Drivers ### Increasing Cancer Incidence The rising incidence of cancer in South Korea is a pivotal driver for the car t-cell-therapy market. As the population ages, the prevalence of various cancers, including hematological malignancies, has escalated. Reports indicate that cancer is the leading cause of death in the country, with approximately 300,000 new cases diagnosed annually. This alarming trend necessitates innovative treatment options, such as car t-cell therapies, which have shown promising results in clinical trials. The demand for effective cancer treatments is likely to propel investments in research and development within the car t-cell-therapy market, as healthcare providers seek to improve patient outcomes and survival rates. ### Collaborative Clinical Trials Collaborative clinical trials between academic institutions and pharmaceutical companies are emerging as a significant driver for the car t-cell-therapy market. In South Korea, partnerships are being formed to conduct trials that evaluate the efficacy and safety of new car t-cell therapies. These collaborations not only pool resources but also enhance the quality of research through shared expertise. As a result, the car t-cell-therapy market is likely to see an increase in the number of approved therapies, which could lead to a broader range of treatment options for patients. The success of these trials may also encourage further investment in the market, fostering innovation and development. ### Government Support and Funding Government initiatives and funding play a crucial role in the growth of the car t-cell-therapy market. The South Korean government has been actively promoting biotechnology and healthcare innovation through various funding programs and grants. In recent years, the government allocated over $500 million to support research in advanced therapies, including car t-cell therapies. This financial backing not only encourages research and development but also facilitates collaboration between academic institutions and industry players. As a result, the car t-cell-therapy market is likely to benefit from enhanced research capabilities and accelerated product development, ultimately improving treatment options for patients. ### Growing Awareness and Acceptance There is a notable increase in awareness and acceptance of car t-cell therapies among healthcare professionals and patients in South Korea. Educational initiatives and outreach programs have contributed to a better understanding of the benefits and potential of these therapies. As more healthcare providers become familiar with car t-cell therapies, the likelihood of their adoption in clinical practice increases. This growing acceptance is expected to drive demand within the car t-cell-therapy market, as patients seek out innovative treatment options. Furthermore, as success stories emerge, public perception is likely to shift positively, further enhancing the market's growth prospects. ### Advancements in Genetic Engineering Technological advancements in genetic engineering are significantly influencing the car t-cell-therapy market. Innovations in CRISPR and other gene-editing technologies have enhanced the ability to modify T-cells, making them more effective against cancer cells. In South Korea, research institutions and biotech companies are increasingly focusing on these technologies, which could lead to more personalized and effective therapies. The market is expected to witness a surge in the development of next-generation car t-cell therapies, potentially increasing the overall market size. As these advancements continue, they may also attract funding and partnerships, further stimulating growth in the car t-cell-therapy market. ## Future Outlook The [CAR T Cell Therapy Market](https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102) is projected to grow at a 14.65% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and enhanced regulatory support. **New opportunities:** - Development of personalized CAR T-cell therapies for specific cancer types. - Expansion of manufacturing capabilities to reduce production costs. - Strategic partnerships with healthcare providers for integrated treatment solutions. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in innovative cancer therapies. ## Segment Insights ### By Therapeutic Area: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) In the South Korea car t-cell-therapy market, Oncology remains the dominant therapeutic area, commanding a significant share of the overall market. With advancements in treatments and growing recognition of car t-cell therapies in oncology, this segment's influence continues to grow. Meanwhile, Autoimmune Diseases are experiencing robust growth, appealing to a broader patient demographic that requires innovative treatment solutions. The demand for personalized therapies in this area is spurring investment and development. The growth trends for these segments are influenced by various factors, including technological advancements and increasing clinical trials aimed at expanding treatment options. The rise in prevalence of cancer and autoimmune diseases is driving the need for effective therapies, particularly in oncology, where car t-cell therapies have shown promising results. In contrast, the fast-growing Autoimmune Diseases segment benefits from heightened awareness and a shift toward targeted treatments that offer enhanced efficacy and safety profiles. Oncology: Dominant vs. Autoimmune Diseases: Emerging Oncology remains the dominant therapeutic area in the South Korea car t-cell-therapy market, characterized by a strong pipeline of innovative therapies aimed at various cancer types. This segment benefits from established protocols and a well-defined patient base, ensuring a steady demand for novel treatments. On the other hand, Autoimmune Diseases, while emerging, are gaining traction due to increased recognition of their complexity and the need for specialized therapies. This segment is marked by rapid research and development efforts aimed at tailoring treatments to individual patient needs, reflecting a broader trend toward personalized medicine. Both segments exhibit unique market dynamics, with oncology leading in market share while autoimmune diseases carve out a significant place with fast-paced advancements. ### By Cell Source: Autologous (Largest) vs. Allogeneic (Fastest-Growing) In the South Korea car t-cell-therapy market, the market share among the cell source segment values is predominantly led by autologous therapies, which are favored for their personalized approach. This segment effectively utilizes patient-derived cells, ensuring a tailored treatment plan for each individual. In contrast, allogeneic therapies, though currently smaller in market share, are gaining traction due to their potential for off-the-shelf availability, catering to broader patient populations. Growth trends indicate a significant surge in demand for gene-edited therapies, driven by technological advancements and regulatory support. Allogeneic treatments are emerging as the fastest-growing segment, appealing to healthcare providers looking for more accessible and cost-effective solutions. The drive towards personalized medicine is complemented by ongoing research and clinical trials that continue to validate the efficacy of these treatments, marking a pivotal shift in therapeutic approaches within the market. Autologous (Dominant) vs. Allogeneic (Emerging) Autologous therapies dominate the South Korea car t-cell-therapy market due to their personalized treatment protocol, where T-cells are harvested from the patient, engineered, and reinfused. This method significantly reduces the risk of rejection and enhances treatment efficacy. Conversely, allogeneic therapies are positioning themselves as an emerging alternative, utilizing donor cells to create scalable treatment options that can be stockpiled for immediate use. This shift towards allogeneic treatments not only meets the increasing patient demand but also holds promise for faster administration and broader applicability. As research advances, both segments are expected to coexist, catering to varied patient needs according to clinical requirements and availability. ### By Indication: Acute Lymphoblastic Leukemia (Largest) vs. Multiple Myeloma (Fastest-Growing) In the South Korea car t-cell-therapy market, Acute Lymphoblastic Leukemia holds the largest share, reflecting its established treatment protocols and significant patient population. Non-Hodgkin Lymphoma follows closely, capitalizing on increasing awareness and advancements in therapy. Multiple Myeloma, while currently smaller in share, is growing rapidly due to rising incidence rates and innovative treatment options that enhance patient outcomes. Growth trends in this segment are fueled by ongoing clinical research and the approval of novel therapies, particularly for Multiple Myeloma. The increasing prevalence of hematological cancers and improved diagnosis methodologies contribute to this growth, alongside investments in R&D from key players. Regulatory support for innovative treatments is also enhancing the market landscape, positioning the sector for robust development over the coming years. Acute Lymphoblastic Leukemia (Dominant) vs. Multiple Myeloma (Emerging) Acute Lymphoblastic Leukemia is recognized as the dominant indication in the South Korea car t-cell-therapy market, benefiting from a well-established treatment framework and high medical adoption rates. The comprehensive care protocols have made significant progress in patient survival rates, making it a standard target for CAR T-cell therapies. In contrast, Multiple Myeloma is emerging as a promising area due to its rapidly evolving treatment landscape. Enhanced understanding of the disease, alongside technological advancements in cellular therapies, is propelling its growth. The market is seeing increased investment and research aimed at optimizing outcomes for Multiple Myeloma patients, which positions it as a vital area of focus moving forward. ### By End User: Hospitals (Largest) vs. Cancer Treatment Centers (Fastest-Growing) In the South Korea car t-cell-therapy market, hospitals hold the largest market share, significantly outpacing other end users such as research institutes and cancer treatment centers. Hospitals benefit from established infrastructures and a steady influx of patients requiring advanced therapies, positioning them as key players in the market landscape. Conversely, cancer treatment centers, while smaller in current market share, are rapidly expanding due to increasing patient awareness and the growing prevalence of cancer, driving demand for innovative treatment options. The growth trends for this segment are particularly promising. The surge in cancer cases paired with advancements in car t-cell therapies have propelled cancer treatment centers into a growth phase, marking them as the fastest-growing segment. Increased collaborations between hospitals and these centers are fostering an ecosystem that enhances research and treatment outcomes, underpinning the growth potential within this segment. As more healthcare providers adopt car t-cell therapies, the competitive landscape will evolve, presenting new opportunities for these end users. Hospitals (Dominant) vs. Cancer Treatment Centers (Emerging) Hospitals dominate the South Korea car t-cell-therapy market, primarily due to their comprehensive facilities and ability to provide a broad spectrum of treatments. They are often equipped with advanced technologies and staffed by specialists, enabling efficient delivery of car t-cell therapies. Conversely, cancer treatment centers are emerging as vital contributors to the market, focusing specifically on oncology and innovative therapies. Their tailored services and patient-centric approaches foster rapid growth, as more patients seek specialized care. As these centers continue to enhance their capabilities and technological integration, they are expected to attract a larger patient base, challenging hospitals' dominance in the near future. ## Competitive Benchmarking The car t-cell-therapy market in South Korea is characterized by a dynamic competitive landscape, driven by rapid advancements in biotechnology and increasing investments in personalized medicine. Key players such as Novartis (CH), Gilead Sciences (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Novartis (CH) focuses on innovation through continuous research and development, particularly in expanding its CAR-T offerings. Gilead Sciences (US) emphasizes strategic partnerships to bolster its product pipeline, while Bristol-Myers Squibb (US) is actively pursuing mergers and acquisitions to enhance its therapeutic portfolio. Collectively, these strategies contribute to a competitive environment that is increasingly characterized by innovation and collaboration. In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in the context of South Korea, where regulatory frameworks favor local production. The market structure appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their collective actions shape the competitive dynamics, fostering an environment where innovation is paramount. In October 2025, Novartis (CH) announced a collaboration with a leading South Korean research institute to develop next-generation CAR-T therapies. This partnership is strategically significant as it not only enhances Novartis's R&D capabilities but also aligns with the growing trend of localized innovation in the region. Such collaborations may accelerate the development of therapies tailored to the specific needs of the South Korean patient population. In September 2025, Gilead Sciences (US) launched a new CAR-T product specifically designed for pediatric patients, marking a pivotal expansion of its therapeutic offerings. This move is indicative of Gilead's commitment to addressing unmet medical needs and could potentially capture a significant share of the pediatric oncology market in South Korea. The introduction of this product may also enhance Gilead's reputation as a leader in innovative therapies. In August 2025, Bristol-Myers Squibb (US) completed the acquisition of a biotech firm specializing in CAR-T technology, which is expected to bolster its existing portfolio. This acquisition reflects a broader trend of consolidation within the industry, as companies seek to enhance their technological capabilities and market reach. The integration of new technologies could provide Bristol-Myers Squibb with a competitive edge in the rapidly evolving landscape of cell therapies. As of November 2025, current trends in the car t-cell-therapy market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage shared resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift may redefine how companies position themselves in the market, emphasizing the importance of cutting-edge solutions and sustainable practices. ## Recent News & Developments The South Korea CAR T Cell Therapy Market has seen significant developments recently, with major companies like Bristol-Myers Squibb, Novartis, and Gilead Sciences expanding their presence. In March 2023, Allogene Therapeutics announced a collaboration with Samsung Biologics to enhance its cell therapy manufacturing capabilities in South Korea. Additionally, in April 2023, Sorrento Therapeutics initiated its CAR T Cell development program, focusing on innovative therapies in the region. Mergers and acquisitions have also been noteworthy, with KITE Pharma being acquired by Gilead Sciences in a deal that continues to influence competitive dynamics in the market. Over recent years, specifically in 2021, LG Chem strengthened its Research and Development capabilities by teaming up with local universities to foster innovation in cell therapy technologies. The South Korean government is actively supporting this sector through its Healthcare Innovation Strategy, aimed at boosting biopharmaceutical technologies and expanding access to advanced cancer treatments. The growth in this sector is also reflected in increasing investments aimed at enhancing the local manufacturing landscape for CAR T Cell therapies, thereby improving patient access and treatment options. ## **South Korea****CAR T** ## Report Scope | MARKET SIZE 2024 | 250.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 286.62(USD Million) | | MARKET SIZE 2035 | 1125.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.65% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Bristol-Myers Squibb (US), Celgene (US), Amgen (US), Merck & Co. (US), AstraZeneca (GB), Janssen Pharmaceuticals (US), Bluebird Bio (US) | | Segments Covered | Therapeutic Area, Cell Source, Indication, End User | | Key Market Opportunities | Advancements in personalized medicine and regulatory support enhance growth potential in the car t-cell-therapy market. | | Key Market Dynamics | Rising investment in Research and Development drives innovation in the car T-cell therapy market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the projected market valuation for the South Korea car t-cell-therapy market by 2035?** A: The projected market valuation for the South Korea car t-cell-therapy market by 2035 is $1125.0 Million. **Q: What was the market valuation for the South Korea car t-cell-therapy market in 2024?** A: The market valuation for the South Korea car t-cell-therapy market in 2024 was $250.0 Million. **Q: What is the expected CAGR for the South Korea car t-cell-therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the South Korea car t-cell-therapy market during the forecast period 2025 - 2035 is 14.65%. **Q: Which therapeutic area is projected to have the highest valuation in the South Korea car t-cell-therapy market?** A: The oncology therapeutic area is projected to have the highest valuation, ranging from $100.0 Million to $450.0 Million. **Q: What are the key players in the South Korea car t-cell-therapy market?** A: Key players in the South Korea car t-cell-therapy market include Novartis, Gilead Sciences, Bristol-Myers Squibb, and others. **Q: What is the valuation range for the autologous cell source segment in the South Korea car t-cell-therapy market?** A: The valuation range for the autologous cell source segment is projected to be between $100.0 Million and $450.0 Million. **Q: Which indication is expected to show significant growth in the South Korea car t-cell-therapy market?** A: The non-Hodgkin lymphoma indication is expected to show significant growth, with a valuation range of $100.0 Million to $450.0 Million. **Q: What is the projected valuation for the allogeneic cell source segment by 2035?** A: The projected valuation for the allogeneic cell source segment by 2035 is expected to be between $75.0 Million and $375.0 Million. **Q: Which end user segment is anticipated to dominate the South Korea car t-cell-therapy market?** A: The hospitals end user segment is anticipated to dominate, with a valuation range of $100.0 Million to $450.0 Million. **Q: What is the valuation range for the infectious diseases therapeutic area in the South Korea car t-cell-therapy market?** A: The valuation range for the infectious diseases therapeutic area is projected to be between $75.0 Million and $375.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-car-t-cell-therapy-market-49864*